These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

703 related items for PubMed ID: 17698862

  • 1. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB.
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Van Assche G, Vermeire S, Rutgeerts P.
    Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
    Leung Y, Hanauer SB.
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S202-8. PubMed ID: 20117343
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
    Fiasse R, Denis MA, Dewit O.
    J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 13. [Inflammatory diseases of the intestines].
    Felley C, Guyot J, Hess J, Mottet C, Delarive J, Michetti P.
    Rev Med Suisse; 2006 Jan 18; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
    [Abstract] [Full Text] [Related]

  • 14. Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
    Zhou L, Chen H, Wen Q, Zhang Y.
    Eur J Gastroenterol Hepatol; 2012 Jun 18; 24(6):695-701. PubMed ID: 22387885
    [Abstract] [Full Text] [Related]

  • 15. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW, Fedorak RN.
    Gastroenterol Clin North Am; 2010 Sep 18; 39(3):543-57. PubMed ID: 20951917
    [Abstract] [Full Text] [Related]

  • 16. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
    Peyrin-Biroulet L.
    Am J Gastroenterol; 2013 May 18; 108(5):859-60. PubMed ID: 23644972
    [No Abstract] [Full Text] [Related]

  • 17. New strategies in the management of inflammatory bowel disease.
    Rutgeerts P, Baert F.
    Acta Clin Belg; 1999 Oct 18; 54(5):274-80. PubMed ID: 10555385
    [Abstract] [Full Text] [Related]

  • 18. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I.
    J Physiol Pharmacol; 2009 Dec 18; 60 Suppl 7():67-70. PubMed ID: 20388947
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B.
    Tidsskr Nor Laegeforen; 2007 Jun 14; 127(12):1673. PubMed ID: 17571118
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.